EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRH receptor antagonist crinecerfont – a promising new treatment option for patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Clemens Kamrath iD, Hedi L Claahsen-van der Grinten

Journal of Pediatric Endocrinology and Metabolism · 29.01.2025 · 38 (1) · 16-21

DOI: 10.1515/jpem-2024-0440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, online erschienen am 25.11.2024. Verfasst von Clemens Kamrath und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology and Diabetology, Centre for Paediatrics and Adolescent Medicine, 88751 University of Freiburg , Freiburg, Germany. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Amines, Receptors, Corticotropin-Releasing Hormone, Thiazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

21-Hydroxylase deficiency (21OHD), the most common form of congenital adrenal hyperplasia (CAH), leads to impaired cortisol synthesis and androgen excess. Current treatments of patients with classic 21OHD with supraphysiological doses of glucocorticoids pose risks such as impaired growth and metabolic complications. We discuss the CRH receptor antagonist as a therapeutic option for children with classic 21OHD. A phase three trial of crinecerfont, a CRH receptor antagonist, offers a promising new treatment option. Crinecerfont helped to reduce glucocorticoid doses and to lower androgen levels. However, the study population may not be fully representative of the general 21OHD population. Successful implementation depends on patient adherence and monitoring to avoid possible complications such as adrenal crises. Overall, crinecerfont represents a valuable development, but further research and careful clinical management are needed to optimize its use in CAH treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalAminesReceptors, Corticotropin-Releasing HormoneThiazolesChildHumansClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

21OHDCAHandrogenscrinecerfontsteroid precursors

Substanzen

AminescrinecerfontReceptors, Corticotropin-Releasing HormoneThiazoles

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology and Diabetology, Centre for Paediatrics and Adolescent Medicine, 88751 University of Freiburg , Freiburg, Germany.
  • Department of Pediatrics, Division of Pediatric Endocrinology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, Netherlands.

ORCID-Profile: Clemens Kamrath

Zitieren

APA

Kamrath, C., & Claahsen-van der Grinten, H. L. (2025). CRH receptor antagonist crinecerfont – a promising new treatment option for patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Pediatric Endocrinology and Metabolism, 38(1), 16-21. https://doi.org/10.1515/jpem-2024-0440

Vancouver

Kamrath C, Claahsen-van der Grinten HL. CRH receptor antagonist crinecerfont – a promising new treatment option for patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Pediatric Endocrinology and Metabolism. 2025;38(1):16-21. doi:10.1515/jpem-2024-0440

BibTeX
@article{Kamrath2025,
  author = {Kamrath, Clemens and Claahsen-van der Grinten, Hedi L},
  title = {CRH receptor antagonist crinecerfont – a promising new treatment option for patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency},
  journal = {Journal of Pediatric Endocrinology and Metabolism},
  year = {2025},
  volume = {38},
  number = {1},
  pages = {16--21},
  doi = {10.1515/jpem-2024-0440}
}
Kostenlos starten →